Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 4, 2013, Pages 361-370

  Ono, Yuri ^a   Kameda, Hiraku ^a,b   Cho, Kyu Yong ^a,b  

^a Sapporo Fukoku Seimei Ekimaedori Building   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Mitiglinide; Postprandial hyperglycemia; Self monitoring of blood glucose; Type 2 diabetes mellitus; Voglibose

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; MITIGLINIDE; MITIGLINIDE PLUS VOGLIBOSE; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; VOGLIBOSE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMERUS FRACTURE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; TEST MEAL; TREATMENT DURATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; ISOINDOLES; JAPAN; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84874479873     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.770839     Document Type: Article

References (40)

1. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008;93:1345-50
2. Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-19
3. International Diabetes Federation. 2011 Guideline for management of postmeal glucose in diabetes. International Diabetes Federation, Brussels; 2011
4. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
5. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
6. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
7. DECODE Study Group, European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999;42:647-54
8. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabet Care 1991;14:308-17
9. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4
10. Gao X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009;37:812-21
11. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009;37:1904-12
12. Li L, Yang M, Li Z, et al. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial. Diabet Obes Metab 2012;14:187-9
13. Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2010;44:1615-23
14. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001;431:119-25
15. Malaisse WJ. Mitiglinide: a rapid-and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8
16. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14
17. Vichayanrat A, Ploybutr S, Tunlakit M, et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002;55:99-103
18. Abe M, Okada K, Maruyama T, et al. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:169-76
19. Kaku K, Tanaka S, Origasa H, et al. Concomitant effects of a rapid and short acting insulin secretagogue mitiglinide in type 2 diabetes patients with inadequate control of blood glucose with voglibose monotherapy-phase II/III double blind comparative study. Jpn Pharmacol Ther 2007;35:S51-72; In Japanese
20. Katsuno T, Watanabe N, Nagai E, et al. Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. J Diabet Invest 2011;2:204-9
21. Mori Y, Ojima K, Akabane K, et al. Effect of combination therapy with mitiglinide and voglibose on glucose increases and changes in insulin dynamics after sucrose loading in spontaneously diabetic OLETF rats. Ther Res 2011;32:1475-82; In Japanese
22. Inoue M. Tighter control of postprandial hyperglycaemia with mitiglinide/voglibose fixed-dose combination in patients with type 2 diabetes. Expert Opin Pharmacother 2012;13:2257-68
23. Yoshino G, Tominaga M, Hirano T, et al. The test meal A: A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jap Diab Sci 2006;49:361-71; In Japanese]
24. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diab Invest 2012;3:39-40
25. Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500-3
26. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
27. Phillips DI, Clark PM, Hales CN, et al. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286-92
28. Suwa T, Ohta A, Matsui T, et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J 2010;57:135-40
29. Sakuma N, Omura M, Oda E, et al. Converse contributions of fasting and postprandial glucose to HbA1c and glycated albumin. Diabet Int 2011;2:162-71
30. Yamanouchi T, Ogata N, Tagaya T, et al. Clinical usefulness of serum 1, 5-anhydroglucitol in monitoring glycaemic control. Lancet 1996;347:1514-18
31. Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006;12(Suppl 1):42-6
32. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabet Care 2007;30:263-9
33. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7
34. Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007;39:683-6
35. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009;8:23
36. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabet Obes Metab 2012;14:283-7
37. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009;329:669-76
38. Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabet Care 2010;33:730-2
39. Singhal P, Caumo A, Cobelli C, et al. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism 2005;54:79-84
40. Heine RJ, Diamant M, Mbanya JC, et al. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ 2006;333:1200-4